Harmony Biosciences Holdings Inc (HRMY) Stock Price, Quote & News

Company Profile

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical tr...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 539 9800

Website: www.harmonybiosciences.com

Address:

630 West Germantown Pike, Suite 215, Plymouth Meeting, United States

Night_Owl_Biotech Mar. 22 at 5:00 PM

The attachment lists all commercial-stage non-oncoloy focused bios with FDA approvals between 1/1/2018 & 12/31/2023 noting market cap, actual FY25 revenues & gross margin, 5-year analyst consensus & related revenue multiples. $OCUL is now down 50% its recent high after rejected an enhanced Sanofi offer for more than $16 a share. OCUL FY25 represents Dextenza sales only. The growth is anticipated from Axpaxli that has a Phase 3 reading soon. $HRMY trades at the lowest multiple of FY26 consensus (but has an imminent patent cliff...offset by multiple late-stage reads). $ARDX continues to trade at the lowest multiples in any commercial-stage peer group $XERS hit $10 a share last Halloween & is off 45% since $APLS appears a head scratcher. This is not investment advice.

2 · Reply

TalkMarkets Mar. 20 at 8:50 AM

A Sleepy Stock That Can Wake Up Your Portfolio $HRMY https://talkmarkets.com/article/a-sleepy-stock-that-can-wake-up-your-portfolio-1773996609

0 · Reply

Quantumup Mar. 18 at 10:40 AM

Oppenheimer⬇️the PT on $SLNO to $80 and reiterated at Outperform. $RYTM $HRMY $XBI Oppenheimer said:::We have revised our SLNO model to project a slower US launch ramp vs. our prior estimates as well as reflect a go-it-alone scenario for European commercialization following recent mgmt commentary. Nonetheless, we remain above consensus on 2026 top-line, and see upcoming events (early May's 1Q update, EU regulatory opinion ~mid-year) as offering support to the shares which have underperformed the XBI by ~30% YTD and are down ~60% since their July 2025 highs. We see greater value creation through preservation of EU economics, and recognize that the de-risking of an EMA approval—particularly if the stock is slow to recover—could catalyze an acquisitive move by a global rare disease player. We reiterate our Outperform, but lower our PT to $80 (from $110).

0 · Reply

OfficialStocktwitsUser Mar. 10 at 2:41 PM

$HRMY RSI: 23.68, MACD: -2.0962 Vol: 3.85, MA20: 31.13, MA50: 34.72 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BioTechHealthX Mar. 8 at 4:29 PM

$HRMY Harmony Biosciences Holdings (NASDAQ: HRMY) is gaining attention among biotech investors as its flagship narcolepsy treatment WAKIX continues driving powerful revenue growth. With nearly $870 million in annual product revenue and patient adoption rising steadily, the company is positioning itself as one of the most intriguing profitable biotech stocks in the neurological treatment space. https://biotechhealthx.com/biotech-news/is-harmony-biosciences-holdings-hrmy-a-great-buy/

0 · Reply

BioTechHealthX Mar. 6 at 5:40 PM

$AUPH $BMRN $CPRX $HALO $HRMY Biotech stocks may be starting slow this year, but analysts believe the sector could be setting up for a powerful comeback. With massive pharmaceutical patent expirations approaching and over $1 trillion in industry capital ready for deals, these cheap biotech stocks could offer significant upside for investors searching for undervalued healthcare opportunities. https://biotechhealthx.com/biotech-news/10-cheap-biotech-stocks-to-buy-now/

0 · Reply

Estimize Mar. 5 at 12:00 PM

Wall St is expecting 0.99 EPS for $HRMY Q1 [Reporting 05/05 BMO] http://www.estimize.com/intro/hrmy?chart=historical&metric_name=eps&utm_co

0 · Reply

BillionerOfKing Mar. 3 at 10:19 PM

$HRMY Current Stock Price: $28.28 Contracts to trade: $27.5 HRMY Mar 20 2026 Call Entry: $0.50 Exit: $0.90 ROI: 79% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

RunnerSignals Feb. 25 at 9:23 PM

$ENPH $HRMY $IOVA $ORCL $WDAY upgraded with smart money positioning ahead of key catalysts https://stocksrunner.com/news/2026-02-25-top-stock-upgrades-today-in-the-buzz

0 · Reply

erevnon Feb. 25 at 11:20 AM

B of A Securities maintains Harmony Biosciences Hldgs $HRMY at Underperform and lowers the price target from $32 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Harmony Biosciences to Participate in Upcoming Investor Conferences

Feb 24, 2026, 3:37 PM EST - 4 weeks ago

Harmony Biosciences Holdings, Inc. (HRMY) Q4 2025 Earnings Call Transcript

Feb 24, 2026, 7:30 AM EST - 4 weeks ago

Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion

Feb 17, 2026, 8:05 AM EST - 5 weeks ago

Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy

Feb 10, 2026, 8:05 AM EST - 6 weeks ago

Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Jan 13, 2026, 9:56 PM EST - 2 months ago

Harmony Biosciences Holdings, Inc. (HRMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 8:05 AM EST - 2 months ago

Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation

Jan 7, 2026, 8:05 AM EST - 2 months ago

Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 16, 2025, 6:30 AM EST - 3 months ago

Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG

Dec 8, 2025, 8:05 AM EST - 4 months ago

Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome

Dec 2, 2025, 8:05 AM EST - 4 months ago

Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting

Nov 24, 2025, 8:05 AM EST - 4 months ago

Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation

Nov 19, 2025, 8:05 AM EST - 4 months ago

Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence

Nov 4, 2025, 2:06 PM EST - 5 months ago

Harmony Biosciences Holdings, Inc. (HRMY) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 7:30 AM EST - 5 months ago

Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M

Oct 23, 2025, 8:05 AM EDT - 5 months ago

Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance

Oct 15, 2025, 2:30 PM EDT - 5 months ago

3 Biotech Stocks I Am Accumulating

ADMA INCY SNDX XBI

Oct 6, 2025, 6:23 AM EDT - 6 months ago

Top 3 Health Care Stocks That Are Preparing To Pump In Q4

CRVL MLTX

Sep 24, 2025, 2:18 PM EDT - 6 months ago

Freeport-McMoRan, Harmony Biosciences, Cohu, And Other Big Stocks Moving Lower On Wednesday

COHU FCX

Sep 24, 2025, 8:33 AM EDT - 6 months ago

Harmony Biosciences' genetic disorder drug fails to meet main goal in late-stage trial

Sep 24, 2025, 8:00 AM EDT - 6 months ago

Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome

Sep 15, 2025, 2:18 PM EDT - 7 months ago

11 fast-growing small-cap stocks that could get a boost from the Fed's next move

AGYS ASTH CORT ENVA GSHD HASI KNTK

Sep 5, 2025, 1:09 AM EDT - 7 months ago

Harmony Biosciences Holdings, Inc. (HRMY) Presents at Cantor Global Healthcare Conference 2025 Transcript

Aug 26, 2025, 8:05 AM EDT - 7 months ago

Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress

Aug 21, 2025, 8:05 AM EDT - 7 months ago

Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference

Aug 20, 2025, 4:15 PM EDT - 7 months ago

Harmony Biosciences: Reiterating Buy Ahead Of Data Catalyst For Cannabinoid Drug

Aug 5, 2025, 4:04 PM EDT - 8 months ago

Harmony Biosciences Holdings, Inc. (HRMY) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 7:30 AM EDT - 8 months ago

Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025

Jul 22, 2025, 8:05 AM EDT - 8 months ago

Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025

Jul 15, 2025, 8:05 AM EDT - 9 months ago

Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series

Jun 11, 2025, 8:05 AM EDT - 10 months ago

Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025

Jun 5, 2025, 8:05 AM EDT - 10 months ago

Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation

Jun 4, 2025, 8:05 AM EDT - 10 months ago

Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

May 6, 2025, 5:05 PM EDT - 11 months ago

Harmony Biosciences Holdings, Inc. (HRMY) Q1 2025 Earnings Call Transcript

May 6, 2025, 7:30 AM EDT - 11 months ago

Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance

Apr 29, 2025, 8:05 AM EDT - 11 months ago

Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025

Apr 8, 2025, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Shareholders to Connect

Apr 8, 2025, 8:05 AM EDT - 1 year ago

Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome

Apr 7, 2025, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Shareholders to Reach Out

Apr 6, 2025, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Shareholders to Learn More About the Investigation

Apr 4, 2025, 10:00 AM EDT - 1 year ago

Harmony Biosciences Holdings, Inc. (HRMY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 3, 2025, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Investors to Learn More About the Investigation

Apr 3, 2025, 8:05 AM EDT - 1 year ago

Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors

Apr 2, 2025, 10:00 AM EDT - 1 year ago

Harmony Biosciences Holdings, Inc. (HRMY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Apr 1, 2025, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Investors to Connect

Mar 31, 2025, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Harmony Biosciences Holdings, Inc. (HRMY) Stockholders to Inquire about Securities Investigation

Mar 28, 2025, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Stockholders to Connect

Mar 27, 2025, 10:00 AM EDT - 1 year ago

Harmony Biosciences Holdings, Inc. (HRMY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Mar 26, 2025, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Stockholders to Learn More About the Investigation

Mar 26, 2025, 8:05 AM EDT - 1 year ago

Harmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare Conference

Night_Owl_Biotech Mar. 22 at 5:00 PM

2 · Reply

TalkMarkets Mar. 20 at 8:50 AM

A Sleepy Stock That Can Wake Up Your Portfolio $HRMY https://talkmarkets.com/article/a-sleepy-stock-that-can-wake-up-your-portfolio-1773996609

0 · Reply

Quantumup Mar. 18 at 10:40 AM

0 · Reply

OfficialStocktwitsUser Mar. 10 at 2:41 PM

0 · Reply

BioTechHealthX Mar. 8 at 4:29 PM

0 · Reply

BioTechHealthX Mar. 6 at 5:40 PM

0 · Reply

Estimize Mar. 5 at 12:00 PM

Wall St is expecting 0.99 EPS for $HRMY Q1 [Reporting 05/05 BMO] http://www.estimize.com/intro/hrmy?chart=historical&metric_name=eps&utm_co

0 · Reply

BillionerOfKing Mar. 3 at 10:19 PM

0 · Reply

RunnerSignals Feb. 25 at 9:23 PM

$ENPH $HRMY $IOVA $ORCL $WDAY upgraded with smart money positioning ahead of key catalysts https://stocksrunner.com/news/2026-02-25-top-stock-upgrades-today-in-the-buzz

0 · Reply

erevnon Feb. 25 at 11:20 AM

B of A Securities maintains Harmony Biosciences Hldgs $HRMY at Underperform and lowers the price target from $32 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

d_risk Feb. 24 at 5:40 PM

$HRMY - Harmony Biosciences Holdings Inc - 10K - Updated Risk Factors HRMY flags new risks from expanding WAKIX into pediatric cataplexy, heavier exposure to fast-evolving AI (including cybersecurity, IP, bias and regulatory uncertainty), and mounting U.S. policy pressure on drug pricing and reimbursement under IRA, OBBBA Medicaid cuts, and emerging Trump-era MFN-style proposals. #Pharmaceuticals #PediatricCataplexy #AIRisks #DrugPricingPressure #HealthcarePolicy 🟢 Added 🟠 Removed https://d-risk.ai/HRMY/10-K/2026-02-24

0 · Reply

Itinerant Feb. 24 at 4:45 PM

$HRMY I suggest that the following is a key point to understanding when thinking about this earnings report of today and valuation. The reason that G&A expense was so very high in Q4 was that the company recognized $30 million of litigation expense. This was a one time expense, and therefore must be backed out when attempting to establish the ongoing annuity level of the earnings stream. That accrual appears in current liabilities, of course. Having made this adjustment, one finds that the real, ongoing earnings was $0.94 cents per share in Q4, and the real, ongoing EBITDA was $304 million at the annual rate. The company did a poor job of communicating this point. It will take the analysts some time to understand this. IMO the stock is worth $55.

0 · Reply

Quantumup Feb. 24 at 2:12 PM

Wolfe Research🏁 $CNTA Outperform/$40, and said, The Next Big Idea in CNS - A High-Conviction Orexin Play; Initiate with OP; $40 PT $ALKS $TAK $HRMY $ESALY Wolfe Research added, While multiple orexin-2 agonists demonstrated strong clinical data in late-stage studies, we believe CNTA's ORX750 would become the best-in-class product and generate >$3B US peak sales ➢ Key upcoming catalysts: Additional Ph2 data for higher doses expected in 1Q26, we expect good data which should move the stock up significantly (+40-50%).

0 · Reply

Itinerant Feb. 24 at 2:02 PM

$HRMY Large increase in Q4 G&A expense hurt the P&L a lot.

0 · Reply

StocktwitsEarnings Feb. 24 at 1:17 PM

$HRMY Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.39 down -55.17% YoY • Reported revenue of $243.78M up 21.12% YoY • Harmony Biosciences reiterates 2026 WAKIX net revenue guidance between $1B and $1.04B, projecting blockbuster status in narcolepsy, reflecting the strength and durability of the pitolisant franchise.

0 · Reply

JimmyJam5350 Feb. 24 at 1:45 AM

$HRMY meanwhile their fundamentals are great. The .markets make no sense. Theyre profitable and have no debt issues

0 · Reply

AStrokeOfLuck Feb. 23 at 7:07 PM

$HRMY

0 · Reply

Arcides Feb. 23 at 5:11 PM

$HRMY about 5 years being dog shit...

0 · Reply

Hotstockinggal Feb. 23 at 4:01 PM

$HRMY See Acorda Ampyra case for reference Anti Pharma judges

0 · Reply

Astrobro Feb. 23 at 5:11 AM

$HRMY This stock seems cursed. why has it only crabbed since IPO despite making good revenue? Should be like 3B MC For good commercial product and late stage pipeline. Can anyone tell me why this chart is so crabby?

0 · Reply

BigDaddyCapital Feb. 22 at 7:23 PM

$HRMY it’s patent infringement case against Wakix. Generics vs Harmony, this is extreme uncertainty

0 · Reply

Itinerant Feb. 22 at 4:41 PM

$HRMY No, it was just the failure of ZYN002 trial. This is a non event.

0 · Reply

Market Cap	1.54B
Revenue (ttm)	868.45M
Net Income (ttm)	158.69M
EPS (ttm)	N/A
PE Ratio	10.13
Forward PE	8.23
Profit Margin	18.27%
Debt to Equity Ratio	0.19

Volume	636,200
Avg Vol	911,320
Day's Range	N/A - N/A
Shares Out	57.84M
Stochastic %K	26%
Beta	0.88
Analysts	Sell
Price Target	$42.00